Bortezomib trimer-d15

Bortezomib trimer-d15

• UNSPSC Description: Bortezomib trimer-d15 is deuterium labeled N,N',N''-((2S,2'S,2''S)-(((1R,1'R,1''R)-(1,3,5,2,4,6-Trioxatriborinane-2,4,6-triyl)tris(3-methylbutane-1,1-diyl))tris(azanediyl))tris(1-oxo-3-phenylpropane-1,2-diyl))tris(pyrazine-2-carboxamide)（Bortezomib Impurity）.
• Target Antigen: Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others
• Field of Research: Others
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=NC=CN=C1)N[C@@H](CC2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])C(N[C@H](B3OB(OB(O3)[C@H](CC(C)C)NC([C@@H](NC(C4=NC=CN=C4)=O)CC5=C([2H])C([2H])=C([2H])C([2H])=C5[2H])=O)[C@H](CC(C)C)NC([C@@H](NC(C6=NC=CN=C6)=O)CC7=C([2H])C([2H])=C([2H])C([2H])=C7[2H])=O)CC(C)C)=O
• Molecular Weight: 1113.76
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported